ScinoPharm Taiwan Ltd. is a globally recognized pharmaceutical company delivering end-to-end drug development and manufacturing solutions. Since 1997, ScinoPharm has evolved from an active pharmaceutical ingredient (API) manufacturer into a fully integrated Contract Development and Manufacturing Organization (CDMO), supporting innovators, specialty pharma, and generic drug companies worldwide.
Leadership Driving Innovation and Global Impact
At the helm is Li-An Susan Lu, President and CEO, whose expertise in strategy and operations has transformed ScinoPharm into a comprehensive pharmaceutical solutions provider.
Her leadership focuses on:
- Accelerating drug development timelines
- Strengthening global supply chains
- Ensuring high-quality, compliant manufacturing
- Delivering long-term value to patients and partners
From API Manufacturing to Integrated CDMO Excellence
ScinoPharm’s major transformation came with its expansion into finished dosage formulations, enabling full-service capabilities across the pharmaceutical value chain.
Today, the company offers:
- Complex API development
- Sterile injectable manufacturing
- Formulation and drug product development
- Regulatory and commercialization support
This integrated model reduces operational complexity, shortens timelines, and ensures consistent product quality.
Commitment to Quality, Compliance, and Reliability
ScinoPharm maintains rigorous global standards, with facilities consistently passing inspections by regulatory authorities such as the U.S. Food and Drug Administration (FDA).
Key strengths include:
- Multiple zero-deficiency inspection outcomes
- Strong regulatory compliance systems
- Reliable supply chain continuity
- High standards in sterile and high-potency manufacturing
Even during global disruptions, the company has ensured uninterrupted supply of critical medicines.
Advanced Capabilities in Complex Drug Manufacturing
ScinoPharm specializes in high-barrier pharmaceutical manufacturing, including:
- Oncology injectables
- Central nervous system (CNS) therapies
- Metabolic and hematology treatments
- High-potency sterile injectables
The company has successfully supported global drug launches and continues to expand its own product pipeline, with FDA-approved injectable products and ongoing ANDA submissions.
Innovation Through Technology and Partnerships
Continuous investment in innovation keeps ScinoPharm competitive in a rapidly evolving industry. The company focuses on:
- Process optimization and advanced manufacturing technologies
- High-efficiency production platforms
- Long-term strategic partnerships
By collaborating closely with biotech and pharmaceutical companies, ScinoPharm accelerates development while ensuring operational excellence.
ESG and Sustainable Pharmaceutical Operations
ScinoPharm integrates Environmental, Social, and Governance (ESG) principles into its core strategy:
- Reducing carbon footprint and improving energy efficiency
- Promoting workplace diversity and employee well-being
- Strengthening governance, cybersecurity, and compliance
This approach enhances transparency, sustainability, and long-term business resilience.
Strengthening Global Supply Chain Resilience
To address ongoing global uncertainties, ScinoPharm has implemented:
- Diversified sourcing and manufacturing strategies
- Real-time supply chain monitoring
- Strategic inventory management
These measures ensure consistent delivery of pharmaceutical products across global markets.
Future Vision: Expanding Pharmaceutical Innovation
Looking ahead, ScinoPharm is focused on:
- Expanding complex injectable and combination products
- Advancing capabilities in APIs and drug-device integration
- Targeting high-impact therapeutic areas such as oncology and CNS diseases
The company’s goal is to deliver high-quality, accessible medicines while supporting partners in navigating complex global healthcare challenges.
Advice for Future Biotech Leaders
Susan Lu emphasizes the importance of:
- Understanding the full pharmaceutical value chain
- Embracing continuous learning and innovation
- Building strong collaborations across the industry
Her message to emerging professionals is clear:
“Innovation in healthcare is driven by collaboration, knowledge, and a shared commitment to improving patient outcomes.”